FDA Approves Subcutaneous Use of Atezolizumab and Hyaluronidase-tqjs

Fact checked by Caroline Seymour
News
Article

The agency approved the subcutaneous injection of atezolizumab and hyaluronidase-tqjs for all of the adult indications as the intravenous formulation of atezolizumab.

The FDA has approved the subcutaneous injection of atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for use in all adult indications as the intravenous formulation of atezolizumab (Tecentriq), including non–small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma (ASPS).

FDA Approval

The regulatory decision was supported by data from the phase 3 IMscin001 trial (NCT03735121). Findings showed that the geometric mean ratio (GMR) of subcutaneous atezolizumab and intravenous atezolizumab for Cycle 1Ctrough was 1.05 (90% CI, 0.88-1.24) in patients with with locally advanced or metastatic NSCLC. The AUC0-21days was 0.87 (90% CI, 0.83-0.92).

Data for overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were similar for the subcutaneous and IV formulations.

The most common any-grade adverse effects reported in at least 10% of patients were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.

Recent Videos
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
Experts on lung cancer
Experts on lung cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.